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Background: Inhibition of breast cancer stem cells has been shown to be an effective therapeutic 
strategy for cancer prevention. The aims of this work were to evaluate the efficacy of koenimbin, 
isolated from Murraya koenigii (L) Spreng, in the inhibition of MCF7 breast cancer cells and 
to target MCF7 breast cancer stem cells through apoptosis in vitro.
Methods: Koenimbin-induced cell viability was evaluated using the MTT (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide) assay. Nuclear condensation, cell permeability, mitochon-
drial membrane potential, and cytochrome c release were observed using high-content screening. 
Cell cycle arrest was examined using flow cytometry, while human apoptosis proteome profiler 
assays were used to investigate the mechanism of apoptosis. Protein expression levels of Bax, 
Bcl2, and heat shock protein 70 were confirmed using Western blotting. Caspase-7, caspase-8, 
and caspase-9 levels were measured, and nuclear factor kappa B (NF-κB) activity was assessed 
using a high-content screening assay. Aldefluor™ and mammosphere formation assays were used 
to evaluate the effect of koenimbin on MCF7 breast cancer stem cells in vitro. The Wnt/β-catenin 
signaling pathway was investigated using Western blotting.
Results: Koenimbin-induced apoptosis in MCF7 cells was mediated by cell death-transducing 
signals regulating the mitochondrial membrane potential by downregulating Bcl2 and upregulating 
Bax, due to cytochrome c release from the mitochondria to the cytosol. Koenimbin induced significant 
(P0.05) sub-G0 phase arrest in breast cancer cells. Cytochrome c release triggered caspase-9 activa-
tion, which then activated caspase-7, leading to apoptotic changes. This form of apoptosis is closely 
associated with the intrinsic pathway and inhibition of NF-κB translocation from the cytoplasm to 
the nucleus. Koenimbin significantly (P0.05) decreased the aldehyde dehydrogenase-positive cell 
population in MCF7 cancer stem cells and significantly (P0.01) decreased the size and number 
of MCF7 cancer stem cells in primary, secondary, and tertiary mammospheres in vitro. Koenimbin 
also significantly (P0.05) downregulated the Wnt/β-catenin self-renewal pathway.
Conclusion: Koenimbin has potential for future chemoprevention studies, and may lead to the 
discovery of further cancer management strategies by reducing cancer resistance and recurrence 
and improving patient survival.
Keywords: Murraya koenigii (L) Spreng, koenimbin, MCF7 breast cancer stem cells, nuclear 
factor kappa B, Wnt/β-catenin, glycogen synthase kinase 3β
Introduction
Murraya koenigii (L) Spreng (known as Surabhinimba in Sanskrit), known locally as the 
curry leaf, is a member of the Rutaceae family and is widely distributed in South Asia.1 
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The leaves of M. koenigii are used in food products as a 
flavoring agent.2 Various parts of the plant are also used to 
treat dyspepsia, dysentery, chronic fever, mental disorders, 
nausea, dropsy, and diarrhea,1 as well as for the management 
of diabetes.3–5 Several carbazole alkaloids with significant 
biological activity have been isolated from M. koenigii.1,6,7
Established cell lines pave the way for new perspectives 
in genetic and biological investigations, drug resistance, and 
chemotherapeutic studies in which these cells more truly 
reflect the organs of origin and maintain many characteristics 
of the derived cancer tissue.8,9 Recent studies have indicated 
that phytochemicals have antioxidant, antiproliferative, and 
proapoptotic effects in leukemia and liver, lung, prostate, 
breast, colon, brain, melanoma, and pancreatic cancer, both 
in vitro and in vivo.10–19 The advantages of phytochemicals 
are that they are well tolerated and can be added to the diet. 
Moreover, phytochemicals can be taken on a long-term basis 
to inhibit primary tumor growth or reduce the risk of tumor 
recurrence.20
Recent evidence has shown that a subpopulation of tumor 
cells known as cancer stem cells (CSCs) are the origins of 
and maintain various types of cancer.21,22 Via consecutive 
self-renewal and differentiation, possibly regulated by 
signaling pathways similar to those of normal stem cells, 
this small population of CSCs gives rise to the bulk of the 
tumor.21–24 Additionally, identification of CSCs from blood 
and solid tumors25–33 is paving the way for future researchers 
to evaluate the efficacy of phytochemicals against CSCs. 
The Wnt/β-catenin, hedgehog, and Notch signaling path-
ways, among others, have been identified as key modulators 
of self-renewal of CSCs.23,34 Further, CSCs contribute to 
tumor resistance/relapse due to the inability of chemotherapy 
and radiation therapy to eradicate them.22,35,36
Several bioactive dietary compounds, including 
curcumin,37,38 quercetin, and epigallocatechin gallate,39 have 
been reported to potentially target the self-renewal pathways 
of CSCs and may provide an effective strategy to overcome 
tumor resistance and reduce the risk of relapse.21 The Wnt/β-
catenin signaling pathway plays a key role in promoting 
the self-renewal of breast CSCs.5 Cytoplasmic β-catenin 
translocates to the nucleus and is complexed with the T-cell 
factor/lymphoid enhancer factor, modulating the activation 
of Wnt target genes.21,40 Glycogen synthase kinase (GSK)3β, 
adenomatous polyposis coli, casein kinase 1α, and axin 
regulate intracellular β-catenin levels.41 GSK3β increases the 
degradation of β-catenin through the ubiquitin–proteasome 
pathway via phosphorylation of three specific amino acids, 
ie, Ser33, Ser3, and Thr41.41 In this study, the efficacy 
of koenimbin against MCF7 breast CSCs was examined 
in vitro. Further, the ability of koenimbin to suppress the 
Wnt/β-catenin signaling pathway was investigated.
Materials and methods
Materials
The compound koenimbin, isolated from the leaves of 
M. koenigii with a purity of 98.5%, was a kind gift from 
Mohamed Aspollah Sukari in the Faculty of Science, 
Universiti Putra Malaysia. The chemical and physical proper-
ties of the koenimbin compound used in our work were in full 
agreement with previous reports.42 Cell culture medium, fetal 
bovine serum, penicillin, and streptomycin were obtained 
from Gibco (Invitrogen, Life Technologies, Inc., Rockville, 
MD, USA). Z-VAD-FMK, a pan caspase inhibitor, was 
sourced from R&D Systems (Minneapolis, MN, USA).
cell culture
All American Tissue Culture Collection cells used in this 
study were a gift from Yeap Swee Keong at the Institute 
of Bioscience, Universiti Putra Malaysia. Cells were 
cultured in cell culture flasks and maintained at 37°C in a 
humidified atmosphere with 5% CO
2
. MCF7 human breast 
adenocarcinoma cells were maintained in Roswell Park 
Memorial Institute 1640 medium supplemented with 10% 
heat-inactivated fetal bovine serum and 1% penicillin and 
streptomycin. MCF-10A, a non-tumorigenic epithelial cell 
line, was used as a control and maintained in mammary 
epithelial growth medium, supplemented with additives 
obtained from Clonetics Corporation (MEGM™ kit, catalog 
number CC-3150, Lonza, Walkersville, MD, USA). For 
experimental purposes, cells in the exponential growth 
phase of approximately 70%–80% confluence were used. 
The cells were routinely screened for Mycoplasma species 
using a GenProb detection kit according to the manufac-
turer’s instructions.
MTT cell viability assay
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide) assay was used to determine the viability 
of cells treated with koenimbin. Briefly, 1.0×104 cells were 
seeded in a 96-well plate and incubated overnight at 37°C 
in 5% CO
2
. On the following day, the cells were treated 
with various concentrations of the compound, and incubated 
further at 37°C in 5% CO
2
 for 24, 48, and 72 hours. MTT 
solution was added at 2 mg/mL and after 2 hours of incuba-
tion at 37°C in 5% CO
2
. Dimethyl sulfoxide was added to 
dissolve the formazan crystals. The plates were then read 
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using an Infinite® M200 Pro (Tecan, Männedorf, Switzerland) 
at a 570 nm absorbance wavelength. Cell viability percentage 
after exposure to koenimbin for 24, 48, and 72 hours was 
calculated using a previously described method.43 The IC
50
 
value was defined as the concentration of the compound 
required to reduce the absorbance of treated cells to 50% of 
the absorbance of dimethyl sulfoxide-treated control cells. 
The experiment was carried out in triplicate.
isolation of candidate breast cscs
Candidate MCF7 breast CSCs were isolated from MCF7 
cells by sorting the CD44+/CD24-/low cell population using 
a catcher tube-based cell sorter in combination with a flow 
cytometer (FACSCalibur™, BD Biosciences, Franklin 
Lakes, NJ, USA). The cells were stained with 20 µL of the 
CD44 antibody and 20 µL of the CD24 antibody [CD44 
mouse anti-human monoclonal antibody [clone MEM-85], 
fluorescein isothiocyanate [FITC] conjugate, CD24 mouse 
anti-human monoclonal antibody [clone SN3], phycoeryth-
rin conjugate, mouse immunoglobulin G2b (FITC), mouse 
immunoglobulin G1 (R-phycoerythrin), all sourced from 
BD Biosciences] in a 5 mL tube at a concentration of 107 
cells/mL. The tubes had been incubated in the dark at room 
temperature for 45 minutes. The CD44+/CD24-/low cell popu-
lation was identified by quadrant analysis using CellQuest 
Pro software.
non-adherent mammosphere formation 
assay
CSCs from MCF7 cells were plated in six-well ultralow 
attachment plates (TPP, Fisher Scientific, Waltham, MA, 
USA) at a density of 1,000 cells/mL of culture medium.44 
The cells are able to grow and form spheres in serum-free 
Dulbecco’s Modified Eagle’s Medium/F12 medium (Lonza), 
supplemented with B27 (Invitrogen), 1% antibiotic- 
antimycotic, 5 µg/mL insulin, 1 µg/mL hydrocortisone, 
4 µg/mL gentamicin, 20 ng/mL epidermal growth factor 
(Gibco), 20 ng/mL basic fibroblast growth factor (Gibco). 
Every 2 days, fresh medium including the 1 mL supplements 
were added to each well. The primary culture of MCF7 CSCs 
was incubated with different concentrations of koenimbin 
(0, 1, 2, and 4 µg/mL) for mammosphere-forming conditions. 
The cells from koenimbin-treated primary mammospheres 
were then subcultured to secondary (second passage) and 
tertiary (third passage) cultures for each respective group 
in the absence of koenimbin. After 5–7 days in vitro, the 
number and size of the mammospheres were compared with 
the control, and images were acquired with MetaMorph 
7.6.0.0 using an Eclipse TE2000-S microscope (Nikon, 
Tokyo, Japan).
Aldefluor enzyme assay
A cell population with high aldehyde dehydrogenase (ADH) 
activity was previously reported to enrich mammary stem/
progenitor cells.23 An Aldefluor™ (StemCell Technologies, 
Herndon, VA, USA) enzyme assay was carried out using 
an ADH substrate, BODIPY-aminoacetaldehyde (1 µmol/L 
per 106 cells), according to the manufacturer’s guidelines. 
Briefly, single MCF7 CSCs from cell cultures were incubated 
for 45 minutes at 37°C in 5% CO
2
, and the final result was 
then obtained using a flow cytometer.
cell cycle analysis
MCF7 cells were seeded and incubated overnight at 37°C 
with 5% CO
2
,
 
and then treated with 2.5, 5, or 10 µg/mL 
of koenimbin for 12 hours. The cells were then harvested, 
stained with a BD Cycletest Plus DNA reagent kit (BD 
Biosciences) according to the manufacturer’s protocol and 
subjected to cell cycle analysis using a Guava easyCyte 
8HT benchtop flow cytometer (Merck, Whitehouse Station, 
TX, USA).
Multiple cytotoxicity assay
A Multiparameter Cytotoxicity 3 kit (Cellomics Technol-
ogy, Halethorpe, MD, USA) was used to measure the six 
independent parameters simultaneously, including cell 
loss, nuclear size, morphological changes, mitochondrial 
membrane potential (MMP) changes, cytochrome c release, 
and changes in cell membrane permeability, as described 
elsewhere.45 Briefly, MCF7 cells were seeded and incubated 
overnight at 37°C with 5% CO
2
, and then treated with koen-
imbin for 24 hours. The MMP dye and cell permeability 
dye were then added to the MCF7 cells and incubated for 
30 minutes at 37°C. MCF7 cells were fixed, permeabilized, 
and blocked with blocking buffer (1×) before probing with 
primary cytochrome c antibody and secondary DyLight 
649-conjugated goat anti-mouse immunoglobulin G for 
55 minutes each. Hoechst 33342 staining solution was used to 
stain the nucleus, and 1,000 stained cells were analyzed using 
the ArrayScan™ high-content screening system (Cellomics 
Technology). This system identifies stained cells and reports 
the intensity and distribution of fluorescence in individual 
cells. Images were acquired for each fluorescence channel 
by specific filters. Images and data pertaining to the intensity 
and texture of fluorescence within individual cells, as well 
as the average fluorescence of the cell population within the 
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well was stored in the Microsoft SQL database and analyzed 
by ArrayScan II Data Acquisition and Data Viewer version 
3.0 software (Cellomics Technology).
Bioluminescent assays for caspase activity
A dose-dependent study of caspase-7, caspase-8, and caspase-9 
activity was carried out in triplicate using Caspase-Glo® 
assay kits (Promega, Madison, WI, USA) on a white 96-well 
microplate. A total of 1×104 cells per well was seeded and 
incubated with different concentrations of koenimbin for 
24 hours. Caspase activity was investigated as previously 
described.45,46 Briefly, 100 µL of Caspase-Glo reagent was 
added and incubated at room temperature for 30 minutes. The 
presence of active caspases from apoptotic cells cleaved the 
aminoluciferin-labeled synthetic tetrapeptide, thus releasing the 
substrate for the luciferase enzyme. Caspase activity was mea-
sured using an Infinite 200 Pro microplate reader (Tecan).
nF-κB translocation
Briefly, 1.0×104 cells were seeded in a 96-well plate and 
incubated overnight at 37ºC with 5% CO
2
. The cells were 
pretreated with different concentrations of the compound 
for 3 hours and then stimulated with 1 ng/mL of tumor 
necrosis factor (TNF)-α for 30 minutes. The medium was 
removed and the cells were fixed and stained with a nuclear 
factor kappa B (NF-κB) activation kit (Thermo Scientific) 
according to the manufacturer’s instructions. The plate was 
examined on an ArrayScan high-content screening reader. 
Calculation of the cytoplasmic and nuclear NF-κB intensity 
ratio was carried out using Cytoplasm to Nucleus Translo-
cation BioApplication software. The average intensity of 
200 cells per well was quantified, and the ratios were then 
compared with TNF-α-stimulated, treated, and untreated 
cells.47
Human apoptosis proteome profiler 
array
To investigate the pathways by which koenimbin induces 
apoptosis, we performed a determination of apoptosis-related 
proteins using a proteome profiler array (human apoptosis 
antibody array kit, Raybiotech, Norcross, GA, USA), accord-
ing to the manufacturer’s instructions. In short, the cells were 
treated with koenimbin 9 µg/mL for 24 hours, in which 300 µg 
of protein extract from each sample were incubated with the 
antibody array membrane for 12 hours. The membrane was 
quantified using a Biospectrum AC ChemiHR 40 system 
(UVP, Upland, CA, USA) and the membrane image file was 
analyzed using ImageJ analysis software.
Protein expression of apoptotic markers 
and the Wnt/β-catenin self-renewal 
pathway
MCF7 cells were treated in T-25 flasks with various con-
centrations of koenimbin. The protein extracts were lysed 
with cell lysis buffer (50 mM Tris-HCl pH 8.0, 120 mM 
NaCl, 0.5% NP-40, 1 mM phenylmethylsulfonyl fluoride), 
and 40 µg of protein extract was loaded onto a 10% sodium 
dodecyl sulfate polyacrylamide gel electrophoresis system, 
then transferred to a polyvinylidene difluoride membrane 
(Bio-Rad Laboratories, Hercules, CA, USA). The membrane 
were then blocked using 5% non-fat milk in TBS-Tween 
buffer 7 (0.12 M Tris-base, 1.5 M NaCl, 0.1% Tween 20) 
for 40 minutes at room temperature. The membrane was 
incubated with the appropriate primary antibody for 
12 hours at 4°C and then washed with Tris-Buffered Saline 
and Tween 20 (TBST) buffer. The primary antibodies for 
detection of apoptotic markers,16,17 ie, β-actin (1:5,000), 
Bcl2 (1:1,000), Bax (1:1,000), and heat shock protein (HSP) 
70 (1:1,000) were purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA, USA). The phospho β-catenin T41+S45 
(1:1,000), phospho β-catenin S33+S37 (1:500), GSK3β 
(1:5,000), phospho GSK3β (1:500), and cyclin D1 (1:5,000) 
for detection of the Wnt/β-catenin self-renewal pathway were 
purchased from Abcam (Cambridge, UK). The membranes 
were then incubated for one hour at room temperature with 
goat anti-mouse or goat anti-rabbit secondary antibodies con-
jugated with alkaline phosphatase (i-DNA, Ocean, NJ, USA) 
at a ratio of 1:5,000 and then washed twice with TBST for 
10 minutes on an orbital shaker. The blots were then devel-
oped using BCIP®/NBT solution (Santa Cruz Biotechnology) 
for a period of 5–30 minutes to detect the target protein band 
as a precipitated dark-blue color.
statistical analysis
Experimental data are presented as the mean ± standard 
deviation of three independent experiments. Normality and 
homogeneity of variance assumptions were checked. The 
statistical analysis was performed using Statistical Package 
for the Social Sciences version 16.0 (SPSS Inc, Chicago, IL, 
USA) and GraphPad Prism version 3.0 (GraphPad Software 
Inc, La Jolla, CA, USA) software. Statistical significance 
was defined at P0.05.
Results
MTT cell viability assay
The effect of koenimbin on MCF7 and MCF-10A cells was 
evaluated using MTT assays in a dose-dependent manner 
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(Table 1). IC
50
 values obtained for the MCF7 cells after 
24, 48, and 72 hours of treatment with koenimbin were 
9.42±1.05 µg/mL, 7.26±0.38 µg/mL, and 4.89±0.47 µg/mL, 
respectively (Figure 1).
cD markers in breast cscs
In this research, breast CSCs (CD44+/CD24-/low) were first 
isolated from MCF7 cells by sorting based on cell surface 
CD44+/CD24-/low marker expression (Figure 2). They were 
then cultured in mammosphere forming conditions. Breast 
CSCs from MCF7 were identified by expression of the 
cell surface marker CD44 and no or weak expression of 
CD24.
inhibitory effect of koenimbin 
on mammosphere formation
Mammosphere cultures were carried out in serum-free 
medium. The mammospheres were photographed and the 
numbers of mammospheres were counted under a Nikon 
Eclipse TE2000-S microscope. Photographs were acquired 
with MetaMorph 7.6.0.0 (Figure 3A and B). It has been 
shown that mammary stem/progenitor cells are enriched 
in non-adherent spherical clusters of cells, termed mam-
mospheres.34 Hence, we exposed MCF7 CSC spheres to 
various concentrations of koenimbin to assess whether 
koenimbin could suppress the formation of mammospheres 
in vitro. According to our results, koenimbin inhibited 
non-adherent spherical clusters of breast CSCs in vitro, 
such that these cells were not capable of yielding second-
ary spheres and differentiating along multiple lineages. 
As shown in Figure 3C–F, koenimbin suppressed the 
formation of spheres, with the number of spheres declining 
significantly (P0.01) with increasing concentrations of 
koenimbin.
inhibitory effect of koenimbin in an  
aDh-positive cell population
MCF7 breast cancer cell populations with high ADH activ-
ity, indicating enriched breast stem/progenitor cells and 
promoting self-renewal of MCF7 CSCs, were assessed 
using the Aldefluor assay (Figure 3G). As shown in Figure 
3H, koenimbin concentrations of 1, 2, and 4 µg/mL sig-
nificantly diminished the ADH-positive population of 
MCF7 CSCs by over 25%, 50%, and 80%, respectively. 
This finding indicates that koenimbin reduced the breast 
MCF7 CSC population in vitro. An interesting observa-
tion is that koenimbin was able to inhibit MCF7 CSCs at 
concentrations of 1, 2, and 4 µg/mL, which hardly affected 
the bulk of the population of MCF-10A cells, implying 
that koenimbin probably has the capacity to preferentially 
target MCF7 CSCs.
cell cycle analysis
According to the cell cycle analysis, treatment with koen-
imbin 10 µg/mL was able to induce significant (P0.05) 
Table 1 ic50 concentration of koenimbin
Cell line IC50 (µg/mL)
24 hours 48 hours 72 hours
McF7 9.42±1.05 7.26±0.38 4.89±0.47
McF-10a 31±0.78 27±1.02 21±0.35
Note: results are shown as the mean ± standard deviation of three independent 
experiments.
Figure 1 MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. 
growth curve for koenimbin-treated McF7 cells at 24, 48, and 72 hours.
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cell populations. McF7 cancer stem cells were treated with koenimbin 1, 2, or 4 µg/mL for 4 days and subjected to Aldefluor assay and flow cytometry analysis. Koenimbin 
decreased the percentage of aDh-positive cells. Data are shown as the mean ± standard deviation (n=3). *P0.05 versus control; **P0.01 versus control. 
Abbreviations: aDh, aldehyde dehydrogenase; K, koenimbin.
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Table 2 effect of koenimbin on cell cycle phases of McF7
Concentration Sub-G0 G0–G1 S G2/M
control 5.92±1.62 60.65±2.94 9.00±0.30 24.43±1.15
2.5 5.75±1.06 61.60±2.02 11.45±0.46 21.20±1.47
5 6.38±1.65 60.40±1.58 10.57±0.49 22.65±1.38
10 76.12±2.49* 17.17±2.08* 2.29±0.24* 4.42±0.32*
Notes: cells were exposed to koenimbin at various concentrations (0, 2.5, 5, 
or 10 µg/ml) and incubated for 24 hours. The table summarizes the percentages 
of cells in each phase of the cell cycle after treatment with koenimbin. Data in the 
same vertical column but different rows refer to the same phase of the cell cycle 
and different koenimbin concentrations. *Indicates a significant difference (P0.05). 
Data are shown as the mean ± standard deviation (n=3).
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Figure 4 cell cycle histograms from analyses of McF7 cells treated with 0 (A), 2.5 (B), 5 (C), and 10 µg/ml (D) of koenimbin for 12 hours. (E) summary of cell cycle 
progression for control and koenimbin-treated McF7 cells.
Notes: Data are shown as the mean ± standard deviation (n=3). *P0.05 versus control.
alteration of all cell cycle phases (Table 2). A dramatic 
increase in the sub-G0 phase, which indicates DNA frag-
mentation, and reduction of the G0/G1, S, and G2/M phases 
was observed in cells treated with koenimbin 10 µg/mL. 
However, no significant difference was observed in cells 
treated with koenimbin 2.5 or 5 µg/mL (Figure 4A–E). 
Therefore, the cell cycle analysis indicated significant cyto-
toxicity and cell inhibitory effects of koenimbin in MCF7 
breast cancer cells.
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effects of koenimbin on membrane 
permeability, MMP, and cytochrome 
c release
As the main source of cellular reactive oxygen species and 
adenosine triphosphate, the mitochondria play an impor-
tant regulatory role in controlling the survival and death 
of cells. We used MMP fluorescent probes to examine the 
function of mitochondria in treated and untreated MCF7 
cells. As shown in Figure 5, the untreated cells were 
strongly stained with MMP dye in comparison with cells 
treated with koenimbin 9 µg/mL for 24 hours. The reduc-
tion in MMP fluorescence intensity indicated that MMP 
was destroyed in the treated cells. A significant increase 
in cell membrane permeability was also observed in the 
treated cells after 24 hours of treatment with koenimbin. 
Twenty-four hours of exposure to koenimbin also resulted 
in an increase in cytochrome c in the cytosol when com-
pared with the control.
Bioluminescent assays for caspase activity
Excessive production of reactive oxygen species from the 
mitochondria and collapse of MMP may activate down-
stream caspase molecules, leading to apoptotic cell death. 
To examine this, we measured the bioluminescent intensi-
ties relating to caspase activity in the MCF7 cells treated 
with different concentrations of koenimbin for 24 hours. As 
shown in Figure 6, a significant dose-dependent increase in 
caspase-7 and caspase-9 activity was detected in the treated 
cells, while no marked change in caspase-8 activity was 
observed between treated and untreated cells. Hence, apop-
tosis induced by koenimbin in MCF7 cells is mediated via 
the intrinsic mitochondrial caspase-9 pathway and not the 
extrinsic death receptor-linked caspase-8 pathway.
Translocation of nF-κB
NF-κB is a transcription factor critical for cytokine gene 
expression. Activation of NF-κB in response to inflammatory 
Hoechst
Control
Koenimbin
(9 µg/mL)
Membrane
permeability MMP Cytochrome c Merged
Figure 5 representative images of McF7 cells treated with medium alone and koenimbin 9 µg/ml, and stained with hoechst for nuclear, cytochrome c, membrane 
permeability, and MMP dyes, and cytochrome c dye. The images from each row are obtained from the same field of the same treatment sample (magnification 20×). 
Abbreviation: MMP, mitochondrial membrane potential.
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cytokines, such as TNF-α, mediates nuclear migration to 
enable DNA-binding activity and facilitate target gene expres-
sion. As seen in Figure 7A, koenimbin suppressed the trans-
location of cytoplasmic NF-κB to the nucleus. The significant 
decline in nuclear NF-κB translocation in TNF-α-stimulated 
MCF7 cells treated with koenimbin as shown by the statisti-
cal analysis confirms the inhibitory activity of the compound 
against nuclear translocation of NF-κB (Figure 7A and B).
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Figure 7 (A) Photographs of intracellular targets in stained McF7 cells treated with koenimbin for 3 hours and then stimulated for 30 minutes with TnF-α 1 ng/ml (nF-κB 
activation). (B) Representative bar chart indicating a significant decline in average fluorescent intensity of nuclei NF-κB, confirming that koenimbin inhibited TNF-α-induced 
translocation of nF-κB from the cytoplasm to the nucleus.
Notes: Data are shown as the mean ± standard deviation (n=3). *P0.05 versus control. 
Abbreviations: nF-κB, nuclear factor kappa B; TnF-α, tumor necrosis factor alpha.
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Figure 8 Quantitative analysis of the human apoptosis proteome profiler array in koenimbin-induced MCF7 cells. MCF7 cells were lysed and protein arrays were performed. 
cells were treated with koenimbin 9 µg/ml for 24 hours and total cell protein was extracted. equal amounts (300 µg) of protein from each control and treated sample were 
used for the assay. Quantitative analysis of the arrays showed differences in the apoptotic markers. 
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effect of koenimbin on apoptotic markers
After exposure of MCF7 cells to koenimbin for 24 hours, the 
cells were lysed and apoptotic markers were examined using 
a human apoptosis protein array. In Figure 8A–D, the images 
represent the changes of apoptotic markers in treated and 
untreated cells. The most important markers involved in the 
apoptosis signaling pathway, such as Bax, Bcl2, caspase-7, 
and caspase-8, were induced, along with cytochrome c. 
HSP70, a significant chaperone involved in apoptosis, was 
also downregulated in this in vitro model.
Protein expression of apoptotic markers 
and the Wnt/β-catenin self-renewal 
pathway
Although many proteins associated with apoptosis were 
observed to be upregulated or downregulated in the protein 
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array, proteins such as Bax and HSP70 were significantly 
induced.
The role of the mitochondria in modulation of apoptotic 
markers at the protein level was examined, and expression 
of Bax, a proapoptotic protein, and Bcl2, an antiapoptotic 
protein, were increased and decreased, respectively, in 
koenimbin-induced MCF7 cells. Further, protein expres-
sion of HSP70 was downregulated in a dose-dependent 
manner (Figure 9). Additionally, treatment of MCF7 cells 
with koenimbin decreased expression levels of β-catenin and 
cyclin D1 (Figure 10A), while the expression level of p-β-
catenin (Ser33/Ser37/Thr41) increased (Figure 10B). In this 
study, MG132 was used to suppress proteasome functional 
activity and determine the status of p-β-catenin (Ser33/Ser37/
Thr41) in response to koenimbin. Here, our result indicated 
reduced expression of p-GSK3β (Ser9) with increasing 
 concentrations of koenimbin (Figure 10C). The koenimbin-
induced β-catenin phosphorylation is reversed in the pres-
ence of LiCl, a GSK3β inhibitor (Figure 10D). As shown in 
Figure 10D, koenimbin has the ability to decrease LiCl-induced 
GSK3β phosphorylation and accumulation of β-catenin.
Discussion
Apoptosis is associated with many biochemical changes in 
cells, including nuclear fragmentation, change in the MMP, 
and regulation of caspases.48 The present study is the first 
report on the in vitro effects of koenimbin, a natural com-
pound derived from the plant M. koenigii (L) Spreng, against 
MCF7 cells and derived MCF7 stem cells/progenitors. Inter-
estingly, koenimbin inhibited the growth of MCF7 cells and 
derived MCF7 stem cells/progenitors, while non-invasive 
MCF-10A cells were more resistant to koenimbin-mediated 
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Figure 9 Western blot analysis of koenimbin in selected apoptotic signaling markers.
Notes: The blot densities are expressed as fold of control (A). The HSP70 protein level was also downregulated, showing significant changes on treatment with koenimbin 
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Figure 10 Western blot analysis of the Wnt/β-catenin self-renewal pathway in McF7 cells treated with koenimbin. Koenimbin downregulated this pathway. 
Notes: Koenimbin decreased protein expression levels of β-catenin and cyclin D1 in McF7 cells (A). Koenimbin increased the phospho-β-catenin ser33/ser37/Thr41, 
whereas licl suppressed phosphorylation through inactivation of gsK3β (B). Koenimbin decreased the expression level of p-gsK3β, while the protein expression of total 
gsK3β was unchanged (C). Koenimbin decreased β-catenin and licl-induced gsK3β phosphorylation, while licl elevated the protein expression level of β-catenin through 
gsK3β phosphorylation (D). each experiment was performed three times (n=3). 
Abbreviation: gsK, glycogen synthase kinase.
antiproliferative activity than the MCF7 cells and derived 
MCF7 CSCs. However, several chemotherapeutic drugs, 
including vincristine, vinblastine, and paclitaxel are derived 
from plants49 and affect normal cells.50
The cell morphology, cell membrane permeability, 
and nuclei area were significantly diminished by treatment 
with koenimbin. Due to their role in direct activation of 
the  apoptotic program in cells, the mitochondria have been 
described as key players in the apoptotic process.51 Therefore, 
the complex role of the mitochondria in apoptosis of MCF7 
cells was investigated by detection of changes in MMP, as it 
is assumed that its disruption is the onset of formation of the 
mitochondrial membrane transition pore.52 The high content 
analysis conducted in this research indicated that koenimbin 
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may target the mitochondria, causing loss of MMP, and 
subsequently, leads to apoptotic changes. Apoptotic proteins, 
such as cytochrome c, are relocalized due to this reduction in 
MMP and permeability transition pore complex.53
The activation of caspase is a key regulatory factor in 
apoptosis.54 In the intrinsic pathway, release of mitochon-
drial cytochrome c into the cytosol is a fundamental feature 
of apoptosome formation and downstream caspase-9 acti-
vation, leading to activation of effector caspases such as 
caspase-3, caspase-6, and caspase-7.55–57 There is evidence 
that members of the Bcl2 protein family are key mediators of 
cytochrome c release in the context of apoptotic stimuli.58,59 
Moreover, release of cytochrome c to the cytosol, loss of 
MMP, and induction of mitochondrial permeability transition 
events, occur as a consequence of movement of Bax into the 
mitochondria.60 The release of cytochrome c and the enzyme 
activity of caspase-7 and caspase-9 triggered by koenimbin 
clearly demonstrated that the apoptosis was via the intrinsic 
pathway. However, the extrinsic pathway of caspase activa-
tion involves signal transduction through cell death receptors 
such as Fas and TNF-α, resulting in caspase-8 activation, 
which in turn activates downstream effector caspases, such as 
caspase-3 and caspase-7.45,61 Caspase-8 activation is closely 
involved with apoptosis signaling via the extrinsic pathway,57 
and may be interlinked with the mitochondrial pathway 
via cleavage of Bid to tBid.62 In agreement with previous 
studies,19,45,63 we observed significant translocation of cyto-
plasmic NF-κB to the nuclei, activated by TNF-α. Our study 
revealed the effectiveness of koenimbin on TNF-α-related 
apoptosis-inducing ligands in MCF7 cells by interfering 
with the NF-κB-induced antiapoptotic signaling pathway, 
release of cytochrome c from the mitochondria into the 
cytosol, sequential activation of caspase-7 and caspase-9, and 
involvement of the up-regulating Bax and down-regulating 
Bcl-2 protein expressions.
According to CSC theory, a variety of cancers are driven 
and preserved by a small proportion of CSCs, thus leading to 
new approaches involving target CSCs for the treatment and 
prevention of cancer.24,64 Previous studies have shown that 
CSCs can cause tumor resistance, relapse, and recurrence.65,66 
A novel approach is required to specifically target the 
CSC population, due to the lack of efficacy of current 
chemotherapies with regard to cancer cells and CSCs. Thus, 
therapies directed against both cancer cells and CSCs may be 
advantageous in the treatment of cancer.24,67,68 Several dietary 
compounds, including curcumin37,38 and sulforaphane,69 have 
been shown to have chemopreventive effects against CSCs. 
Here, the anticancer activity of koenimbin against breast 
CSCs was investigated in vitro to identify the chemopreven-
tive activity of koenimbin and the implications of CSC theory. 
However, we did not undertake a clinical trial of koenimbin 
in breast cancer patients in the present study.
Techniques such as mammosphere culture, cell surface 
markers, and ADH assays have been reported as part of the 
isolation and characterization of breast CSCs in vitro. Iso-
lation and expansion of mammary stem/progenitor cells70 
using mammosphere cultures are based on the failure of 
 differentiated cells to survive and grow in serum-free sus-
pension, compared to stem/progenitor cells.71 Consistent 
with previous studies72 showing that mammospheres are 
composed primarily of CSCs, our observations indicate 
that koenimbin significantly suppressed formation of breast 
stem cell mammospheres, suggesting that koenimbin may 
target breast CSCs from MCF7 cells. Another method for 
distinguishing between mammary stem/progenitor cells 
and differentiated cancer cells involves use of cell markers, 
eg, CD44+/CD24-/low and ADH positivity.26,71,73 It has been 
shown that as few as 500 ADH-positive cells can generate 
a breast tumor within 40 days, while 50,000 ADH-negative 
cells are unable to form tumors.73 ADH-positive cells and 
the CD44+/CD24-/low marker were identified as the highest 
tumorigenic capacity, generating tumors from as few as 20 
cells.73 In contrast, ADH-positive cells without the CD44+/
CD24-/low marker were able to produce tumors from 1,500 
cells, whereas ADH-negative cells and 50,000 CD44+/CD24-/
low cells could not.73 Therefore, Aldefluor assays were used to 
evaluate targeting of breast CSCs by koenimbin. According 
to our results, koenimbin could selectively inhibit ADH-
positive cancer cells in vitro. Interestingly, the concentrations 
of koenimbin that effectively inhibited breast CSCs in both 
the non-adherent mammosphere formation assay and Alde-
fluor assay indicate the significant potential of koenimbin to 
target breast CSCs.
Curcumin has been shown to interfere with the Wnt 
and Notch self-renewal pathways in colonic and pancreatic 
cancer cells, respectively.37,38 Quercetin and green tea epigal-
locatechin gallate were described to regulate key mediators 
of the Wnt and Notch signaling pathways in human colon 
cancer cells.39 Wnt and NF-κB signaling pathways have 
emerged as having hallmark roles in chronic inflammation, 
immunity, development, and tumorigenesis. These two path-
ways independently initiate oncogenesis, and crossregulation 
between these two pathways influences development and 
carcinogenesis.74 It has been reported that β-catenin is down-
regulated in HeLa and HepG2 cells.75 Consistent with these 
studies, we showed that koenimbin was able to  downregulate 
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the Wnt/β-catenin self-renewal pathway and cyclin D1, 
in which the koenimbin-induced β-catenin at Ser33/37/Thr41 
and degradation of the proteasome is possibly via GSK3β 
activation in breast cancer cells, as one of the possible 
mechanisms to target the MCF7 CSCs.
Conclusion
In conclusion, koenimbin is able to trigger apoptosis in breast 
cancer cells in vitro. Treatment of human MCF7 breast cancer 
cells with koenimbin resulted in apoptosis, with cell death-
transducing signals regulating MMP by downregulating Bcl2 
and upregulating Bax, thereby triggering release of mitochon-
drial cytochrome c to the cytosol. Upon entering the cytosol, 
cytochrome c activates caspase-9, then triggers activation of 
caspase-7, and consequently cleaves specific substrates lead-
ing to apoptosis through the intrinsic pathway. Additionally, 
koenimbin is able to target MCF7 CSCs as determined by 
the mammosphere formation assay and Aldefluor assay. Our 
study also identified downregulation of the Wnt/β-catenin 
self-renewal pathway as one of the possible mechanisms of 
action of koenimbin. In conclusion, this study demonstrates 
the therapeutic potential of koenimbin in the chemopreven-
tion of breast cancer, and provides a strong rationale for 
clinical evaluation of this compound in the future.
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